Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety

Respiratory Medicine

Volumn 91, Issue SUPPL. A, 1997, Pages 22-28

  Derendorf, H ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE; TRIAMCINOLONE ACETONIDE;

ASTHMA; CIRCADIAN RHYTHM; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; HUMAN; HYDROCORTISONE RELEASE; INHALATIONAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0030724891     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(97)90102-5     Document Type: Article

References (23)

1. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84 Suppl. A: 25-29.
2. Ryrfeldt A, Andersson P, Edabaecker S, Toensson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63 (Suppl. 122): 86-95.
3. Shenfield GM, Evans ME, Walker SR, Paterson JW. The fate of nebulised salbutamol (albuterol) administered by intermittent positive pressure respiration to asthmatic patients. Am Rev Respir Dis 1973; 108: 501-505.
4. 2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified activator device. Br J Clin Pharmacol 1993; 36: 445-450.
5. Falcoz C, Mackie A, McDowall J, et al. Oral bioavailability of fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 459P-460P.
6. Derendorf H, Hochhaus G, Rohatagi S, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995; 35: 302-305.
7. Chaplin MD, Rooks W, Swenson EW, Cooper WC, Nerenberg C, Chu NI. Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 1980; 27: 402-413.
8. Möllmann H, Meibohm B, Hochhaus G, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol (submitted).
9. Brogden RN, McTavish D. Budesonide: An update review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44: 375-407.
10. Rohatagi S, Hochhaus G, Möllmann H, et al. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral and inhaled administration. J Clin Pharmacol 1995; 35: 1187-1193.
11. Tomlinson RV, Runkel R, Chaplin MD, Bowens L, Kanagy J, Chu N. In vitro studies on the binding of cloprednol to human plasma proteins. J Steroid Biochem 1982; 16: 75-80.
12. Rohatagi S, Bye A, Falcoz C, et al. Dynamic modelling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996; 36: 938-941.
13. Martin LE, Harrison C, Tanner RJN. Metabolism of beclomethasone dipropionate by animals and man. Postgrad Med J 1975; 51: 11-20.
14. Mackie A, Ventresca G, Fuller R, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 539-542.
15. Thorsson L, Edsbacker S, Conradson T. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler p-MDI. Eur Respir J 1994; 7: 1839-1844.
16. Jenner WN, Kirkham DJ. Immunoassay of beclomethasone 17,21- dipropionate and metabolites. In: Reid E, Robinson J D, Wilson I, eds. Bioanalysis of drugs and metabolites. Plenum, New York: 1988: 77-86.
17. Chaplin MD, Cooper WC, Segre EJ, Oren J, Jones RE, Nerenberg C. Correlation of flunisolide plasma levels to eosinopenic response in humans. J Allergy Clin Immunol 1980; 65: 445-453.
18. Falcoz C, Kirby S, Smith J, Olsson P, Ventresca P. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate. Eur Respir J 1996; 9(Suppl.23): 162S.
19. Möllmann H, Derendorf H, Barth J, et al. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol (submitted).
20. Würthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Zeit Wissensch 1992; 137: 161-167.
21. Rohatagi S, Bye A, Mackie A, Derendorf H. Mathematical modelling of cortisol circadian rhythm and cortisol suppression, Eur J Pharm Sci 1996; 4: 341-350.
22. Meibohm B, Hochhaus G, Möllmann H, et al. A PK/PD-approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Biopharm Clin Pharmacokinet (submitted).
23. Meibohm B, Hochhaus G, Rohatagi S, et al. Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol (submitted).